Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients.
about
Essential thrombocythemiaBlast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factorsTreatment of polycythemia vera and essential thrombocythemia: the role of pipobromanComparison of different criteria for the diagnosis of primary myelofibrosis reveals limited clinical utility for measurement of serum lactate dehydrogenase.Red cell mass measurement in patients with clinically suspected diagnosis of polycythemia vera or essential thrombocythemia.Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.Essential thrombocythemia (ET): moving from palliation to cure.How I treat essential thrombocythemia.Essential thrombocythaemia: challenges and evidence-based management.A critical reappraisal of the WHO classification of the chronic myeloproliferative disorders.Anagrelide for control of thrombocytosis due to myeloproliferative disorders.Classification of Ph-negative chronic myeloproliferative disorders--morphology as the yardstick of classification.Myelofibrosis--what's in a name? Consensus on definition and EUMNET grading.Subcellular mislocalization of the transcription factor NF-E2 in erythroid cells discriminates prefibrotic primary myelofibrosis from essential thrombocythemia.Risk of second primary malignancies in a population-based study of adult patients with essential thrombocythemiaJAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasmsExperimental therapeutics for patients with myeloproliferative neoplasias.How we diagnose and treat essential thrombocythaemia.Leukemic transformation in patients with myeloproliferative neoplasms: a population-based retrospective study.Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN) using the Delphi method.Essential thrombocythemia: a review of the clinical features, diagnostic challenges, and treatment modalities in the era of molecular discovery.JAK2 V617F mutation, multiple hematologic and non-hematologic processes: an association?A Rare Presentation of Extramedullary Hematopoiesis in Post-polycythemic Myelofibrosis.The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis.Myelofibrotic transformation in essential thrombocythemia.Second malignancies in essential thrombocythemia (ET): a retrospective analysis of 331 patients with long-term follow-up from a single institution.Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis.The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates.The JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosis.Long-term follow-up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to JAK2/CALR/MPL mutational status.[Differential diagnosis of myeloproliferative neoplasms. Quantitative NF-E2 immunohistochemistry for differentiating between essential thrombocythemia and primary myelofibrosis].Increased serum lactate dehydrogenase isoenzymes in Ph-negative chronic myeloproliferative diseases: a metabolic adaptation?
P2860
Q21202968-F0FF7BA4-0770-4E62-B786-9CEBEB6FA5BDQ26777265-D6068D28-D77E-46C9-9426-F11C1A380CAEQ28210858-0B90CB7D-E8BC-41CF-BE1B-F8F3A3DB7147Q33390032-50BFBC51-4B15-4E21-BDF2-9BAFEFC0514EQ33401757-0B481164-5A89-4B9C-B7E8-B8D38C15F28FQ33442613-0A59FEFD-4838-41AF-891F-C706669FBE50Q35022117-D950C139-0301-4B59-BE03-D47C3010902BQ35132271-C7144A78-63A4-4F16-9D26-D8070ED2720AQ36200476-23DA72ED-0070-4477-95AE-5197D742E13BQ36362041-0855EDC5-F08A-42DA-913C-1C31F996CAE4Q36429566-28AA3AF9-4260-4F19-B5D4-DBF80E6BE91DQ36857937-E1F28B5C-0822-4BC2-A82B-022399A56C90Q36857952-B27E8FC6-4A33-4E5E-BB52-5F72186808A5Q36983755-8D34BAF6-3D16-4A20-91A6-6B60219993E0Q37153294-8ACDC962-28CF-48F0-BA52-E766C976FDBEQ37168138-AB8D399C-4363-4102-898C-BD6DED7822CBQ37797983-EED5B82A-F29F-4524-8943-661022D2EF43Q38606595-8ED78C5C-4A72-4EAB-A403-20D11A73F964Q38673830-A742733E-9232-49D9-B26E-9E83F72E2236Q38742500-F7840524-CDE6-4303-81C3-745127483648Q39306368-26DE03A3-AE65-4773-A7D6-4F87977EB53AQ41499758-820E1F71-4779-4E92-80DB-053E21213BC6Q42065360-64FEBE9B-13BC-45BF-9899-C33DBF44A052Q42385052-259A3508-50BB-43B8-B09A-19247ACD7898Q43171563-4969D018-B0BC-4673-AF64-EB695A89E404Q46364019-316ED52F-A27C-40CE-B9C6-7D350BF09692Q46636672-6AF8B6B7-5FC0-4C39-82C9-8DE4704303A2Q46753346-C307B13C-F791-463E-915C-17DB237719AAQ51355964-A01BE6EF-2121-4581-9B78-2E96AAB352B8Q54262553-5970F019-6848-48BC-9AA2-681F4E14A85BQ54611640-A9A78416-AA9D-4FEF-81A4-16B6DC9D08B3Q55042855-0A80930E-5BDE-4D14-B432-2F7DD0B67F3A
P2860
Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Myelofibrosis with myeloid met ...... n in a series of 195 patients.
@en
Myelofibrosis with myeloid met ...... n in a series of 195 patients.
@nl
type
label
Myelofibrosis with myeloid met ...... n in a series of 195 patients.
@en
Myelofibrosis with myeloid met ...... n in a series of 195 patients.
@nl
prefLabel
Myelofibrosis with myeloid met ...... n in a series of 195 patients.
@en
Myelofibrosis with myeloid met ...... n in a series of 195 patients.
@nl
P2093
P2860
P1476
Myelofibrosis with myeloid met ...... n in a series of 195 patients.
@en
P2093
Alberto Alvarez-Larrán
Carme Talarn
Emilio Montserrat
Francisco Cervantes
Marta Gómez
P2860
P304
P356
10.1046/J.1365-2141.2002.03688.X
P407
P577
2002-09-01T00:00:00Z